A mixed-valence iron complex of the antitumour drug 6-mercaptopurine: tris(6-mercaptopurine)iron(II) tetrachloroferrate(III) chloride

Authors
Schmalle, HW Gyr, E Dubler, E
Citation
Hw. Schmalle et al., A mixed-valence iron complex of the antitumour drug 6-mercaptopurine: tris(6-mercaptopurine)iron(II) tetrachloroferrate(III) chloride, ACT CRYST C, 56, 2000, pp. 957-959
Citations number
17
Categorie Soggetti
Physical Chemistry/Chemical Physics
Journal title
ACTA CRYSTALLOGRAPHICA SECTION C-CRYSTAL STRUCTURE COMMUNICATIONS
ISSN journal
01082701 → ACNP
Volume
56
Year of publication
2000
Part
8
Pages
957 - 959
Database
ISI
SICI code
0108-2701(200008)56:<957:AMICOT>2.0.ZU;2-H
Abstract
Single crystals of the title complex, tris(1,6-dihydro-9H-purine-6-thione-N (7),S)iron(II) tetrachloroferrate(III) chloride, [Fe(C5H4N4S)(3)][FeCl4]Cl , were grown on the surface of solid 6-mercaptopurine monohydrate pellets i n a solution of iron(III) chloride. The solution of the hexagonal structure required the application of twin refinement techniques. All the component ions lie on threefold rotation axes. The complex contains distorted octahed ral [Fe(C5H4N4S)(3)](2+) cations with three N7/S6-chelating neutral 6-merca ptopurine ligands, tetrahedral [FeCl4](-) anions with a mean Fe-Cl distance of 2.189 (1) Angstrom, and free chloride ions.